The Devastating Legacy of Chikungunya in East Africa: Unveiling the Truth Behind the Pain
The silent crisis amidst global headlines. While the world's attention was gripped by the Zika virus outbreak in 2016, a different mosquito-borne illness was wreaking havoc in East Africa, causing debilitating symptoms and leaving a trail of unanswered questions.
In the coastal county of Kilifi, Kenya, a mysterious illness with neurological symptoms was hospitalizing newborns. Prof. George Warimwe, a dedicated scientific investigator, embarked on a mission to uncover the truth. Initial tests ruled out Zika, leading Warimwe and his team to explore other potential causes, including the mosquito-borne Chikungunya virus.
"Chikungunya, a name derived from the Makonde language meaning 'to become contorted,' perfectly describes the agonizing joint pain and fever it inflicts," Warimwe explains. "It's a cruel illness that can persist for months or even years, robbing people of their ability to work or even walk. In children, it can lead to cognitive issues and impaired consciousness."
Warimwe's suspicions were confirmed. Approximately 1 in 10 children hospitalized with neurological illness in a referral hospital in Kilifi were found to be infected with Chikungunya. Some of these children were just weeks old, suggesting in-utero transmission.
This revelation was a wake-up call. While the world battled Zika, Kenya faced its own mosquito-driven crisis, quietly enduring the impact of Chikungunya.
Chikungunya's Resurgence and the Need for Action
Nearly a decade later, Kenya is taking proactive measures to combat Chikungunya. Enhanced disease surveillance, testing, and mosquito tracking have led to the reporting of over 600 cases this year alone.
This surge in cases is part of a global trend. Nearly half a million infections have been identified since January, with hotspots in Brazil and India, and new flare-ups in the Indian Ocean islands. Locally acquired cases have even been detected for the first time in China, New York, and Paris. European countries have also reported hundreds of travel-related Chikungunya cases.
In Kenya, most infections this year have been recorded in Mombasa, a region neighboring Kilifi. However, experts believe these case reports are just the beginning.
"Chikungunya's symptoms, such as fever and joint pain, mimic those of malaria and dengue, leading to frequent misdiagnoses," Warimwe points out. "Clinicians are still unraveling the full spectrum of symptoms, and the lack of necessary diagnostics adds to the complexity."
ACHIEVE: Unlocking the Truth and Saving Lives
A new disease detection program, led by Warimwe and funded by CEPI, is launching this week to bridge this knowledge gap. Medical staff at ten hospitals and clinics across Kenya and Tanzania have been trained to screen every patient presenting with fever or neurological symptoms suggestive of Chikungunya infection.
"Participation is voluntary, but the potential public health benefits are significant," Warimwe emphasizes.
The study, named Accelerating CHIkungunya burden Estimation to inform Vaccine Evaluation (ACHIEVE), aims to spot illnesses early, provide care, and track the virus's spread. With up to $10.3 million in support from the Coalition for Epidemic Preparedness Innovations (CEPI), the study will not only track the overall disease burden but also focus on Chikungunya infections in pregnant women and potential mother-to-child transmission.
For CEPI, which specializes in vaccine development against infectious diseases, ACHIEVE is a crucial step. Understanding who is most affected and where will guide the design of new vaccine trials and inform decisions on vaccine distribution.
"These insights could help us prioritize children and their mothers or identify other vulnerable groups at risk," says Gabrielle Breugelmans, Director of Epidemiology and Data Science at CEPI. "It's about ensuring protection reaches those who need it most."
The study will also assess different Chikungunya virus strains, evaluate the economic impact on local health systems and communities, and measure immune responses across different age groups and over time.
Climate Change and the Spread of Chikungunya
Over a two-year period, ACHIEVE will assess patients with fever or neurological illness and pregnant women at the time of delivery. This comprehensive approach will provide insights into Chikungunya's behavior over an extended period and its potential correlation with seasonal weather changes.
"Warmer, wetter climates create ideal conditions for infected mosquitoes to expand their territories," Breugelmans warns. "The Chikungunya hotspots of today may not be the same tomorrow, so we must remain vigilant."
The ACHIEVE study team, including scientists from the University of Oxford, University of Nairobi, Kenya Medical Research Institute (KEMRI)-Centre for Global Health Research, KEMRI-Wellcome Trust Research Programme, and the Ifakara Health Institute in Tanzania, is dedicated to alleviating the pain and suffering caused by this debilitating illness.
"Our previous work highlighted Chikungunya's prevalence in young children," Warimwe says. "Now, with ACHIEVE, we aim to determine the true extent of the disease in East Africa and direct lifesaving interventions to those who need them most."
The battle against Chikungunya is far from over, but with initiatives like ACHIEVE, there is hope for a brighter, healthier future.
